Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center-Reference-Cited by-同舟云学术

Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center

Published:2022-04-11 Issue:6 Volume:57 Page:1025-1027
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Borogovac Azra^ORCID,Keruakous Amany,Bycko Michelle,Holter Chakrabarty Jennifer,Ibrahimi Sami,Khawandanah Mohamad^ORCID,Selby George B.,Yuen Carrie^ORCID,Schmidt Sarah,Autry Marcus T.,Al-Juhaishi Taha,Wieduwilt Matthew J.,Asch Adam S.

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-022-01664-z.pdf

Reference12 articles.

1. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331–42.

2. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.

3. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–48.

4. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 2020;396:839–52.

5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–44.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention;Blood Advances;2024-08-15

2. A quest for stakeholder synchronization in the CAR T-cell therapy supply chain;Frontiers in Bioengineering and Biotechnology;2024-08-08

3. Mobilizing CARs: Benefits, Drawbacks, and Directions for Outpatient CAR T-cell therapy;Seminars in Hematology;2024-08

4. Tumor burden in ZUMA-7: less is more;Blood;2024-06-13

5. Mechanisms and management of CAR T toxicity;Frontiers in Oncology;2024-05-21